紫杉醇联合卡铂在宫颈癌新辅助化疗中的50例临床分析

Clinical analysis of paclitaxel combined carboplatin in neoadjuvant chemotherapy of cervical cancers 50 cases

目的探讨紫杉醇联合卡铂(TC方案)在宫颈癌新辅助化疗中的临床疗效。方法选取2003年1月至2007年6月在郑州大学第二附属医院经病理确诊的50例宫颈癌患者,回顾分析其临床资料。结果 TC方案新辅助化疗的临床有效率为94%,临床完全缓解的患者6例,占12%,部分缓解的患者41例,占82%,临床稳定的患者3例,占6%,无进展病例;47例化疗后行广泛子宫切除加盆腔淋巴结清扫术,术后病理报告切缘均未见癌转移;6例术后病理报告宫颈局部未见浸润癌,其中3例经多处取材未见癌残留,3例变为原位癌;淋巴结转移的患者有12例,占24%,术后追加放射治疗;所有患者随访至2008年6月底,除3例因期别较晚,化疗效果不满意转外院行放射治疗失访外,未见复发病例。结论宫颈癌TC方案的术前全身新辅助化疗操作方法简便,可提高其近期疗效,值得推广应用。

Objective To investigate the effect of paclitaxel combined carboplatin（TC） in neoadjuvant chemotherapy of cervical cancers. Methods Retrospective analysis of clinical data of 50 patients with cervical cancer who accepted the treatment of neoadjuvant chemotherapy from January 2003 to June 2007. Results Overall clinical response was 94%. 6 patients（6/50） showed complete remission after chemotherapy, 41 cases （41/50） showed partial remission and no progressive disease. In clinically stable 3 patients（6% ） 47 cases used radical hysterectomy and pelvic lymphadenectomy of after chemotherapy,postoperatire pathological report showed no metastasis resection margin. 6 cases postoperative pathological repotrt showed no invasion of carcinoma of cervix local ,3 of them underwent multiple sampling showed no cancer residual,other 3 cased as for cancer. Lymph node metastasis in 12 cases（24% ）. Postoperative supplementary radiotherapy. All patients were followed up until June. 2008, no cases of recurrence except 3 cases lost of follow up because the effect of chemotherapy was not satisfactory transferred to other hospital for radiation therapy. Conclusions The neoadjuvant chemotherapy of paclitaxel combined carboplatin is effective for treating cervical cancers.